Schulman named chair of Alnylam, Bertozzi joins board
Plus: Estigarribia becomes InterVenn CEO and updates from Lyndra, Catalio, Pneumagen and more
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Amy Schulman would succeed Michael Bonney as chair. Schulman was elected to the board in 2014 and is co-founder and executive chair of Lyndra Therapeutics Inc.; managing partner at Polaris Partners; and a board member of SQZ Biotechnologies Co. (NYSE:SQZ) and Mount Sinai Hospital in New York. Bonney, who as executive chair had focused on integrating the compliance and ethics functions at Alnylam, will continue on the board as a non-independent director.
The RNAi company also announced the addition of Carolyn Bertozzi to its board. Bertozzi won the Nobel Prize for chemistry in 2022 and has co-founded several biopharmas, including glycoproteomics company InterVenn BioSciences. ...